Study identifies new role for breast cancer susceptibility gene

A recently discovered facet of the breast cancer susceptibility gene BRCA1 reveals a mechanism linking mutation of BRCA1 to formation of large blood vessels needed to support cancer progression. The findings demonstrate that, in addition to an impaired DNA damage response associated with cancer initiation, mutation of BRCA1 is also linked to manipulation of the tumor microenvironment. The research appears in the July issue of Cancer Cell, published by Cell Press.

Mutations in the breast cancer susceptibility gene BRCA1 account for up to 50% of hereditary breast cancers. BRCA1 is known to serve as a tumor suppressor by regulating DNA damage repair and maintaining genomic stability. Although the mechanism is not fully understood, reduced BRCA1 expression is also often correlated with accelerated growth and progression of breast tumors and with increased tumor blood vessel formation. In order to better understand the link between BRCA1 and tumor progression, Dr. Wen-Hwa Lee and colleagues from the Department of Biological Chemistry at the University of California, Irvine, designed a series of experiments to search for genes that are regulated by BRCA1.

The researchers used microarray analyses to identify genes repressed by BRCA1 or a related tumor suppressor, CtIP, in mammary epithelial cells (MECs). Among the 12 genes inhibited by BRCA1 or CtIP was the gene for a secreted factor, called ANG1, that enhances blood vessel growth and maturation. The researchers found that a defect in a repressor complex formed by BRCA1, CtIP, and another known transcription repressor, ZBRK1, released the gene for ANG1 from repression and promoted survival of neighboring blood vessel cells and formation of capillary-like structures. Further studies demonstrated that mouse mammary tumors deficient in BRCA1 display high levels of ANG1 expression, prominent vascularization, and accelerated growth.

"Our study finds that BRCA1 possesses a role in tumor suppression beyond maintaining genomic stability by regulating intercellular signaling within the tissue microenvironment. This view will extend BRCA1's tumor suppression function to the surroundings that influence the fate of neighboring cells and fortify the pathogenic relevance of its defect to neoplastic growth," concludes Dr. Lee.


The researchers include Saori Furuta, Ju-Ming Wang, Shuanzeng Wei, Yung-Ming Jeng, Xianzhi Jiang, Bingnan Gu, Phang-Lang Chen, Eva Y.-H.P. Lee, and Wen-Hwa Lee of the University of California, Irvine College of Medicine in Irvine, California.

This work was supported by grants from the National Institutes of Health (RO1 CA94170 to W.-H.L.; R37 CA049649 to E.Y.-H.P.L.), a predoctoral fellowship from the Department of Defense (W81XWH-05-1-0322 to S.F.), and a physician scientist award from the National Health Research Institute in Taiwan to Y.-M.J.

Furuta et al.: "Removal of BRCA1/CtIP/ZBRK1 repressor complex on ANG1 promoter leads to accelerated mammary tumor growth contributed by prominent vasculature." Publishing in Cancer Cell 10, 13–24, July 2006. DOI 10.1016/j.ccr.2006.05.022

Last reviewed: By John M. Grohol, Psy.D. on 21 Feb 2009
    Published on All rights reserved.



Adversity introduces a man to himself.
~ Albert Einstein